Atlas Trials

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Clinical trial NCT05555589 · RECRUITING

Trial details

NCT number
NCT05555589
Sponsor
ReGenTree, LLC
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Neurotrophic Keratopathy
Start date
2023-04-11
Primary completion
2026-04-30
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.